Company profile
Oubari Pharma company profile
Oubari Pharma manufactures and markets generic pharmaceuticals across multiple therapeutic areas. The portfolio includes Zolpim (zolpidem tartrate) for short‑term treatment of insomnia, Glitom (miglitol) for management of type 2 diabetes, lincomycin formulations for serious infections, and analgesics indicated for mild to moderate pain. Operations include sterile manufacturing alongside oral solid dosage forms, supported by internal quality control and regulatory processes. Activities span formulation development, production of finished medicines, and publication of product information on indications, dosage, and administration. Dosage strengths and presentations vary by product as listed in official leaflets. Products are distributed under the Oubari brand.
Business identity
- Website
- https://www.oubari.com
- Contact email
- [email protected]
- Phone number
- +963 21 5788980
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00501-01000 employees
- Revenue range
- $50K+
- Founded
- 1989-01-01
Headquarters
- Headquarters
- Lysá pod Makytou, Trenčín Region, Slovakia
- Country code
- SK
- Continent
- Europe